Published in Proc Natl Acad Sci U S A on April 01, 1988
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol (1990) 4.85
Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol (1988) 4.13
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol (1991) 3.71
Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med (1992) 3.40
Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci U S A (1989) 3.31
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol (1994) 2.36
V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol (1993) 2.27
The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue. J Virol (1990) 2.04
Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol (1990) 1.90
Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol (2003) 1.59
Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia. J Virol (1990) 1.53
Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One (2011) 1.41
Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages. J Clin Microbiol (1993) 1.40
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J Virol (1996) 1.22
V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 1.17
Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture. J Virol (1993) 1.12
Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease. Clin Exp Immunol (1994) 1.05
Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques. J Virol (2001) 1.02
Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. J Virol (1991) 1.00
Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog (2014) 0.90
Proteomic analysis of HIV-infected macrophages. J Neuroimmune Pharmacol (2010) 0.85
Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody. J Virol (1990) 0.85
B cell responses to HIV and the development of human monoclonal antibodies. Clin Exp Immunol (1992) 0.82
Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses. Immunology (1992) 0.81
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol (2008) 0.79
HIV p24 as scaffold for presenting conformational HIV Env antigens. PLoS One (2012) 0.77
Can HIV p24 be a suitable scaffold for presenting Env antigens? Clin Vaccine Immunol (2011) 0.76
HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions. J Immunol Res (2015) 0.76
Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression. Clin Diagn Lab Immunol (1995) 0.75
In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge. PLoS One (2013) 0.75
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
Nucleotide sequence of the AIDS virus, LAV. Cell (1985) 16.81
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med (1981) 14.62
Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature (1985) 12.08
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science (1984) 11.30
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science (1984) 10.38
Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell (1986) 9.01
The epidemiology of AIDS: current status and future prospects. Science (1985) 8.73
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (1985) 6.65
A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology (1956) 6.41
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology (1985) 6.08
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A (1986) 5.55
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (1986) 5.25
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature (1985) 5.10
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Human immunodeficiency viruses. Science (1986) 4.34
AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology (1985) 4.30
High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A (1985) 3.35
Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol (1987) 3.19
Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet (1985) 2.88
Structural proteins of mammalian oncogenic RNA viruses: murine leukemia virus neutralization by antisera prepared against purified envelope glycoprotein. J Virol (1974) 1.87
Patterns of antibody response in individuals infected with the human immunodeficiency virus. J Infect Dis (1987) 1.86
Antibody to lymphadenopathy-associated virus in AIDS. N Engl J Med (1985) 1.59
Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes. Virology (1981) 1.43
Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae. Vaccine (1987) 1.15
Natural immunity in mice to the envelope glycoprotein of endogenous ecotropic type C viruses: neutralization of virus infectivity. J Virol (1977) 0.98
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA (1987) 7.24
Xenotropic viruses: murine leukemia viruses associated with NIH Swiss, NZB, and other mouse strains. Science (1973) 7.12
Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology (1985) 6.08
The San Francisco Men's Health Study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-86. Am J Public Health (1987) 5.78
Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication. Proc Natl Acad Sci U S A (1987) 5.65
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol (1990) 4.85
Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science (1995) 4.51
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Human immunodeficiency viruses. Science (1986) 4.34
AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology (1985) 4.30
Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet (1997) 3.93
Condoms prevent transmission of AIDS-associated retrovirus. JAMA (1986) 3.78
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet (1996) 3.54
Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 3.42
High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A (1985) 3.35
Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci U S A (1989) 3.31
Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals. J Infect Dis (1985) 3.31
Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A (1995) 3.23
Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet (1988) 3.21
Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol (1987) 3.19
Molecular cloning of AIDS-associated retrovirus. Nature (1985) 3.16
Human immunodeficiency virus can productively infect cultured human glial cells. Proc Natl Acad Sci U S A (1987) 3.14
Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood (2001) 3.00
Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet (1985) 2.88
Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J Virol (1991) 2.87
Human lymphoblastoid lines from lymph node and spleen. Cancer (1968) 2.85
Demonstration of biological activity of a murine leukemia virus of New Zealand black mice. Science (1970) 2.79
Indirect immunofluorescence tests with sera from African children and cultured Burkitt lymphoma cells. J Bacteriol (1966) 2.79
Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol (1990) 2.72
The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. Am J Public Health (1988) 2.69
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Persistent noncytopathic infection of normal human T lymphocytes with AIDS-associated retrovirus. Science (1985) 2.58
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol (1994) 2.52
Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci U S A (1994) 2.48
Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet (1986) 2.43
Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA (1987) 2.43
Studies with hydroxyurea. I. The reversible inhibition of bacterial DNA synthesis and the effect of hydroxyurea on the bactericidal action of streptomycin. Biochim Biophys Acta (1966) 2.42
CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest (1991) 2.40
The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science (1989) 2.40
AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts. Science (1986) 2.34
A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology (1989) 2.33
Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. J Infect Dis (1987) 2.32
CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci U S A (1995) 2.27
Differential effects of nef on HIV replication: implications for viral pathogenesis in the host. Science (1989) 2.25
Infection by the retrovirus associated with the acquired immunodeficiency syndrome. Clinical, biological, and molecular features. Ann Intern Med (1985) 2.15
Autoimmunity and neoplasia. The possible role of C-type viruses. Am J Clin Pathol (1974) 2.09
The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue. J Virol (1990) 2.04
Murine xenotropic type C viruses I. Distribution and further characterization of the virus in NZB mice. J Virol (1975) 2.02
Virus-specific neutralization by a soluble non-immunoglobulin factor found naturally in normal mouse sera. Proc Natl Acad Sci U S A (1975) 2.01
Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol (1990) 2.00
Prevalence of antibodies to AIDS-associated retrovirus in single men in San Francisco. Lancet (1985) 1.98
Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science (1993) 1.97
Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet (1991) 1.92
Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol (1990) 1.90
An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol (1993) 1.89
Patterns of antibody response in individuals infected with the human immunodeficiency virus. J Infect Dis (1987) 1.86
Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria. Virology (1986) 1.81
Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol (1988) 1.79
Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells. J Clin Microbiol (1988) 1.78
Xenotropic type C viruses. Curr Top Microbiol Immunol (1978) 1.78
CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res Hum Retroviruses (1992) 1.75
Role of the laboratory in ensuring global access to ARV treatment for HIV-infected children: consensus statement on the performance of laboratory assays for early infant diagnosis. Open AIDS J (2008) 1.74
Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J Virol (1991) 1.72
Characterization of a noncytopathic HIV-2 strain with unusual effects on CD4 expression. Science (1988) 1.72
Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol (1994) 1.70
Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. AIDS (1994) 1.68
Long-term cultivation of T-cell subsets from patients with acquired immune deficiency syndrome. Clin Immunol Immunopathol (1985) 1.65
Characterization of human immunodeficiency virus type 1 isolates from children in Romania: identification of a new envelope subtype. J Infect Dis (1994) 1.64
MT-4 plaque formation can distinguish cytopathic subtypes of the human immunodeficiency virus (HIV). Virology (1988) 1.64
Minimal risk of transmission of AIDS-associated retrovirus infection by oral-genital contact. JAMA (1986) 1.62
Host range of murine xenotropic virus: replication in avian cells. Nature (1975) 1.61
Features of HIV-1 that could influence maternal-child transmission. JAMA (1994) 1.58
An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells. Nature (1987) 1.57
Recovery and inactivation of infectious retroviruses from factor VIII concentration. Lancet (1984) 1.56
A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity. J Biol Chem (1995) 1.53
Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol (1995) 1.51
Social distance from the stigmatized. A test of two theories. Soc Sci Med (1982) 1.48
Involving traditional healers in AIDS education and counselling in sub-Saharan Africa: a review. AIDS (1997) 1.47
HIV pathogenesis and long-term survival. AIDS (1993) 1.47
Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. Clin Immunol Immunopathol (1986) 1.44
Studies of FBJ osteosarcoma virus in tissue culture. I. Biologic characteristics of the "C"-type viruses. J Natl Cancer Inst (1973) 1.43
The restricted cellular host range of human herpesvirus 8. AIDS (2000) 1.41
Further studies on a glycolipid formed from dolichyl-D-glucosyl monophosphate. Carbohydr Res (1973) 1.40
Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet (1994) 1.40
Detection of plasma viremia in human immunodeficiency virus-infected individuals at all clinical stages. J Clin Microbiol (1993) 1.40
Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4. J Virol (1993) 1.38
Procedures and discrepancies of blood pressure measurements in two community health centers. Med Care (1982) 1.38
Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. J Infect Dis (1987) 1.36
CD8+ T lymphocyte control of HIV replication in cultured CD4+ cells varies among infected individuals. Cell Immunol (1989) 1.36
Optimal conditions for synthesizing complementary DNA in the HIV-1 endogenous reverse transcriptase reaction. AIDS (1990) 1.35